Poster Session B
Tuesday, September 16, 2014
1:00 p.m. – 3:45 p.m.
Independence & Freedom Ballrooms

B01 Sustained clinical response to treatment directed by genomic expression profiling suggests mTOR signaling is an effective target in choroid plexus carcinoma. Albert Cornelius, Helen DeVos Children's Hospital, Grand Rapids, MI, United States.


B03 Pharmacodynamic Biomarker Evaluation In Phase I Clinical Trials of Selective PI3K and PI3K/mTOR Inhibitors. Yoshito Nakanishi, Genentech Inc., South San Francisco, United States.

B04 NPM1: A new downstream effector of PI3K-AKT-mTOR pathway in prostate cancer? Rafik Boudra, Blaise Pascal University, Clermont-Ferrand, France.

B05 PI3K/mTOR Pathway-Dependent Regulation of Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1alpha Phosphorylation. George Cerniglia, University of Pennsylvania School of Medicine, Philadelphia, PA, United States.

B06 The roles of FoxO transcription factors in mediating AKT activation and renal tumor growth in response to pharmacological inhibition of the PI3K-AKT pathway. Boyi Gan, MD Anderson Cancer Center, Houston, TX, United States.

B07 Estrogen related receptor alpha regulates S6K1 expression and Tamoxifen sensitivity in breast cancer. Subrata Manna, Yeshiva University, New York, NY, United States.

B08 Kicking the addictions: Therapeutic strategies for NSCLC. Abigail Solitro, Van Andel Institute, Grand Rapids, MI, United States.

B09 Targeting the anti-apoptotic protein Mcl-1 with the mTOR inhibitor RAD001 sensitizes luminal breast cancers to the Bcl-2/Bcl-xL inhibitor ABT-263. Michelle Williams, Vanderbilt University, Nashville, TN, United States.

B10 Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in tuberous sclerosis complex. Erik Zhang, Brigham and Women's Hospital, Boston, United States.

B11 PI3-kinase inhibition forestalls the development of drug resistance in BRAFV600E/PTEN\textsuperscript{null} melanoma. Marian Deuker, University of California, San Francisco, San Francisco, CA, United States.
B12 Regulation of the PI3K Pathway by the IKZF1 tumor suppressor and Casein Kinase II in B-cell acute lymphoblastic leukemia. Sinisa Dovat, Pennsylvania State University College of Medicine, Hershey, PA, United States.

B13 Regulation of Akt activity, cell proliferation and viability in ovarian cancer cells by Calcium/Calmodulin-dependent protein kinase kinase 2. Angela Gocher, State University of New York at Buffalo, Buffalo, NY, United States.

B14 Targeting amino acid transport to block mTORC1 and cell cycle in prostate cancer. Jeff Holst, Centenary Institute, Newtown, Nsw, Australia.

B15 Mapping Topology of PI3K/AKT/mTOR signaling in Glioblastoma molecular subgroups. Anna Joy, St. Josephs Hospital & Medical Center, Phoenix, AZ, United States.

B16 Specific antiproliferative and apoptotic effects of AS101 in Ha-Ras but not v-mos transformed fibroblasts: Role of PI3K/Akt and survivin expression. Dvora Kenigsbuch Sredni, bar ilan university, Ramat Gan, Israel.

B17 Targeting PI3K: The PIP2 binding site. Michelle Miller, Johns Hopkins University, Baltimore, United States.

B18 PI3K/mTOR pathway aberrations across diverse solid tumors: Analysis of 13,500 patients. Sherri Millis, Caris Life Sciences, Phoenix, AZ, United States.

B19 Short-chain fatty acids suppress mTOR activation in colon cancer cells via the long non-coding RNA rhabdomyosarcoma 2 associated transcript. Daotai Nie, Southern Illinois University School of Medicine, Springfield, IL, United States.


B21 Oxygen-glucose deprivation activates AMPK through CD38/cADPR/RYR/Ca^{2+}/CaMKII signaling pathway in NQO1 dependent manner. Heon Joo Park, Inha University College of Medicine, Incheon, Korea, Republic Of.

B22 Identification of novel drug combinations to target molecular pathways involved in breast cancer. Vanessa Petroni, University of Malta, Msida, Malta.

B23 The 5' UTR of many oncogenes and transcription factors encodes a targetable dependence on the elf4A RNA helicase. Kamini Singh, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B24 Natural withanolides: A new group of anticancer drugs that selectively target the PI3K-mTOR pathway as novel potent therapeutics against colon cancers in vitro and in vivo. Mark Cohen, University of Michigan, Ann Arbor, Michigan, United States.


B26 PI3K class I and mTOR regulate distinct steps in Met dependent tumourigenesis. Alexia Hervieu, Barts Cancer Institute, London, United Kingdom.
B27 Superoxide Anion $O_2^-$ mediated activation of mTORC2 by Estrogen Receptor in breast cancer cells: Role of acetylation dependent Inhibition of MnSOD. Mehraj Lone, Central Drug Research Institute, Lucknow, Uttar Pradesh, India.

B28 Rictor/mTORC2 drives formation, progression and therapeutic resistance of HER2-amplified breast cancers. Meghan Morrison, Vanderbilt University, Nashville, TN, United States.

B29 High tumor PI3K signaling in resistance to chemoradiotherapy and metastatic dissemination of locally advanced rectal cancer. Anne Ree, Akershus University Hospital, Lorenskog, Norway.

B30 PI3K regulatory subunit p85α plays a tumor suppressive role in mammary epithelial cells. Lauren Thorpe, Harvard Medical School, Boston, MA, United States.


B32 To improve standard of care for glioblastoma patients: mTOR kinase inhibition enhances radiosensitivity in glioblastoma. Anita Tandle, NIH, Bethesda, MD, United States.

B33 Understanding resistance mechanisms to PI3K/mTOR inhibitors in ovarian cancer model systems. Ghassan Tashkandi, University of Edinburgh, Edinburgh, United Kingdom.

B34 Targeting PI3K pathway in spontaneous canine cancers. Shaying Zhao, University of Georgia, Athens, United States.

B35 The brain microenvironment mediates resistance to novel PI3K inhibitors. Vasileios Askoxylakis, Edwin L. Steele Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.


B37 Mechanisms of acquired resistance to the PI3K inhibitor GDC-0941 in breast cancer cell lines. Kyle Edgar, Genentech, South San Francisco, United States.


B39 Targeting cancer stem cells via inhibition of PI3K/AKT pathway alone and in combination with autophagy blockade. Regina Graham, University of Miami, Miami, FL, United States.

B40 Mechanisms of resistance to the α-specific PI3K inhibitor NVP-BYL719 in breast cancer cells harboring PIK3CA mutations. Cedric Leroy, NIBR, Analytical Sciences and Imaging, Basel, Switzerland.

B41 The Hippo pathway effector YAP1 contributes to escape from proliferation arrest under chronic PI3K/mTOR inhibition. Taru Muranen, Harvard Medical School, Boston, MA, United States.

B42 Targetting PI3K in personalized treatment of BRAF-mutated pediatric low-grade gliomas. Aleksandra Olow, University of California, San Francisco, CA, United States.

B43 The immunomodulator AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive via modulation of VLA-4 and downregulation of PI3K. Benjamin Sredni, Bar Ilan University, Ramat Gan, Israel.
B44 Pharmacologic inhibition with IPI-145 and genetic inhibition of PI3K p110δ antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia. Amy Johnson, The Ohio State University, Columbus, OH, United States.


B46 Activity of the novel mTOR inhibitor TORIN-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent AKT reactivation. Luca Neri, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.

B47 mTOR C1/2 activities: Related protein expression and its potential prognostic/therapeutic importance in certain lymphoid malignancies. Anna Sebestyén, Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.

B48 Exploiting aberrant mTOR signaling in hematological malignancies to preferentially enlarge cells for physicochemical destruction. Matthew Trendowski, Syracuse University, Syracuse, NY, United States.

B49 mTORC2 directs breast morphogenesis through Rictor-dependent PKCα/Rac1 signaling independent of Akt. Dana Brantley-Sieders, Vanderbilt University Medical Center, Nashville, TN, United States.

B50 Targeting KRAS G12D colorectal cancer with combined inhibition of PI3K/mTOR and MAPK signaling. Danielle Burgenske, Van Andel Research Institute, Grand Rapids, MI, United States.

B51 The tyrphostin, NT157, suppresses insulin receptor substrates and augments therapeutic response of prostate cancer. Michael Cox, Vancouver Prostate Center, Vancouver, BC, Canada.

B52 Mechanisms of rapalogues’ anti-vascular effects in head and neck cancer. Oleksandr Ekshyyan, Louisiana State University Health - Shreveport, Shreveport, LA, United States.

B53 Targeting PI3K signaling pathway for therapeutic enhancement of verteporfin-mediated photodynamic therapy. Daniel Kraus, University of the Sciences, Philadelphia, PA, United States.

B54 mTOR regulates the tumor-promoting senescence-associated secretory phenotype. Remi-Martin Laberge, Buck Institute for Research on Aging, Novato, California, United States.

B55 mTOR signaling is critical to the development and expansion of preneoplastic foci in a rodent model of progenitor-marker positive hepatocellular carcinoma. Jennifer Sanders, Brown University and Rhode Island Hospital, Providence, RI, United States.

B56 Oxidative stress and MnSOD acetylation promote activation of the PI3K/AKT pathway in uterine fibroids. Vania Vidimar, Northwestern University, Chicago, IL, United States.

B58 A novel small molecule class I PI3K inhibitor TL111 with anti-tumor effects. Dawei Zhang, Teligene Ltd, Suzhou Industrial Park, Jiangsu, China.